TechSeeker Profile

Alnylam Pharmaceuticals Inc (AKA: Alnylam)
Profile last edited on: 8/23/13

Novel therapeutics based on RNA interference, or RNAi
TS Type
Small Corp
Status
Merger
Year Founded
2002
Last Involved Year
2009

Key People / Management

Location Information

300 Third Street 3rd Floor
Cambridge, MA 02142
   (617) 551-8200
   www.alnylam.com

Public Profile

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company organized around RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company's development programs include Vutrisiran, an investigational RNAi therapeutic targeting transthyretin that is in Phase III trials for the treatment of transthyretin-mediated amyloidosis; Givosiran that is in Phase III trials to treat acute hepatic porphyrias; and Lumasiran, an investigational RNAi therapeutic, which is in Phase III clinical trials for glycolate oxidase to treat primary hyperoxaluria type 1. It is also developing Inclisiran, an investigational RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9 that is in Phase III clinical trials for the treatment of hypercholesterolemia; and Fitusiran, an investigational RNAi therapeutic that is in Phase III clinical trials for treating hemophilia A and B with or without inhibitors. In addition, the company engages in the development of Cemdisiran for complement-mediated diseases; ALN-AAT02 to treat alpha-1 anti-trypsin deficiency-associated liver disease; ALN-HBV02 for treating chronic hepatitis B virus infection; and other earlier-stage programs.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
USA
Employment
750
Revenue
N/A
Public/Private
Publicly Traded
Stock Info
NASDAQ : ALNY
Received SBIR $$
Yes

Techseeker firm in the news

There are no news available.